NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock
The TSXV serves as a vital platform for early-stage, high-growth companies, providing access to capital and a strong investor network. In 2024, 80% of the TSXV Venture 50™ companies operated ...
NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation
Eran Ovadya, Chief Financial Officer of NurExone stated, “The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S.